Dung Trinh, MD
Internal Medicine · Mission Viejo, CANPI 1306827670
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $79,954 of the $118,133 with a category attached, or 67.7%. Otsuka America Pharmaceutical, Inc. accounts for 79.1% of it on its own, with 20 other manufacturers making up the rest. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $652.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$93K
- Eisai Inc.$19K
- Genentech, Inc.$2K
- Merck$1K
- Biogen$525
- Otsuka Pharmaceutical Development & Commercialization, Inc.$264
- plus $2K from 15 others
Across 34 payments — averaging $259,891 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7.6M
- E.r. Squibb & Sons, L.L.C.$711K
- Genentech, Inc.$244K
- Biogen$194K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$65K
What the payments were for
- Consulting fees$19,19116%
- Speaking & faculty fees$79,95468%
- Travel & lodging$13,80612%
- Food & beverage$5,1664%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 113 | $93,420 |
| Eisai Inc. | 28 | $19,086 |
| Genentech, Inc. | 1 | $1,875 |
| Merck | 8 | $1,406 |
| Biogen | 6 | $525 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $264 |
| Lilly USA, LLC | 4 | $262 |
| Amgen | 2 | $241 |
| Genentech USA, Inc. | 1 | $150 |
| F. Hoffmann-la Roche AG | 2 | $134 |
| Phathom Pharmaceuticals, Inc. | 1 | $124 |
| Gilead | 1 | $120 |
| Bard Peripheral Vascular, Inc. | 1 | $119 |
| Teva Pharmaceuticals USA, Inc. | 1 | $116 |
| E.r. Squibb & Sons, L.L.C. | 1 | $116 |
| Lundbeck LLC | 1 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Linus Health, Inc. | 1 | $29 |
| GSK | 1 | $28 |
| UCB SA | 1 | $26 |
| GE HealthCare | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$91,887
- Leqembi$18,586
- ADUHELM$358
- VOQUEZNA$124
- Otezla$121
- EVENITY$120
- Vemlidy$120
- ArmonAir Digihaler$116
- ProAir Digihaler$116
- AirDuo RespiClick$116
How this compares
$118,133 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Mission Viejo
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.